69
Participants
Start Date
May 6, 2020
Primary Completion Date
November 30, 2022
Study Completion Date
November 30, 2022
RTX-240
Engineered red cells co-expressing 4-1BBL and IL-15TP
Pembrolizumab
Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
Columbia University Medical Center, New York
UPMC Hillman Cancer Center, Pittsburgh
Thomas Jefferson University, Philadelphia
Virginia Cancer Specialists, Fairfax
Sylvester Comprehensive Cancer Center/UMHC, Miami
Sarah Cannon Research Institute, Nashville
Sarah Cannon Research Institute/ Colorado Blood Cancer Institute, Denver
The Angeles Clinic & Research Institute, Los Angeles
University of California San Diego, La Jolla
Oregon Health & Sciences University - Knight Cancer Institute, Portland
Massachusetts General Hospital, Boston
Lead Sponsor
Rubius Therapeutics
INDUSTRY